Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.
Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →
| Conto economico | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Entrate totali | $42M | $8M | $1M | $4M | $5M | $1M | $0M | $1M | $2M | $2M | $1M |
| Utile lordo | $42M | $7M | $1M | $4M | $5M | $1M | $0M | $1M | $2M | ($7M) | ($5M) |
| Margine lordo% | 100.0% | 86.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -351.5% | -765.9% |
| Risultato Operativo (EBIT) | ($549M) | ($517M) | ($339M) | ($223M) | ($168M) | ($108M) | ($75M) | ($54M) | ($29M) | ($9M) | ($6M) |
| Margine operativo % | -1307.1% | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | -446.3% | -1026.2% |
| Reddito netto | ($502M) | ($465M) | ($298M) | ($215M) | ($160M) | ($107M) | ($73M) | ($50M) | ($27M) | ($9M) | ($6M) |
| Margine netto% | -1195.2% | -6046.2% | -28720.7% | -5345.9% | -3376.7% | -9899.7% | -102625.4% | -4152.1% | -1116.8% | -447.8% | -1021.9% |
| EBITDA | — | ($461M) | ($296M) | ($213M) | ($167M) | ($107M) | ($74M) | ($53M) | ($28M) | ($9M) | ($6M) |
| Utile per azione (EPS) | $-5.06 | $-4.95 | $-3.69 | $-3.69 | $-3.08 | $-2.78 | $-2.39 | $-2.05 | $-2.23 | $-0.66 | $-0.43 |
| Azioni in circolazione (M) | — | 94M | 81M | 58M | 52M | 38M | 30M | 24M | 12M | 14M | 14M |
Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.
Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di CRNX. /companies/us/CRNX
Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.
About TickerBase · Data methodology & sources · Privacy · Terms